Nebraska Cancer Specialists - Midwest Cancer Center Legacy
Nebraska Cancer Specialists
Omaha, NE
Accepting patients
MajesTEC-7
A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
- Has results
Accepting patients
MagnetisMM-30
A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
- Bispecific T Cell Engager (BiTE)
- Bispecific Antibody
- BCMA
- CD3
- Phase 1
- Has results
Accepting patients
CERVINO
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
Accepting patients
Venetoclax Plus Isatuximab and Dexamethasone
A Phase 2 Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Patients With t(11;14)
- Phase 2
- Phase 1/2
- Has results